Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 29, 2019 at 08:18 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 1,033.105 million compared to CNY 1,491.978 million a year ago. Operating loss was CNY 143.376 million compared to operating Income of CNY 149.047 million a year ago. Net loss was CNY 142.943 million compared to net income of CNY 116.706 million a year ago. Basic loss per share from continuing operations was CNY 0.1625 compared to basic earnings per share from continuing operations of CNY 0.1327 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
